Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 1 2

Status

Completed 27Terminated 10Unknown 3Withdrawn 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Melanoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Imatinib Mesylate × Clear all
NCT02812693 2018-04-05

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Ohio State University Comprehensive Cancer Center

Phase 1/2 Withdrawn
Dermatologic

Melanoma

NCT01188889 2015-05-15

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

University of Michigan Rogel Cancer Center

Phase 1/2 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡